Archives for Uncategorized

Template

How did we choose our name? Choosing a name that would reflect this mission wasn't easy. When Chris and Lee founded Nonacus in 2015 they had one singular purpose- To develop non-invasive DNA tests that would change the way genomic diagnostics was done. Choosing a name that would reflect this mission wasn't easy. Based off the Latin term ‘non acus’ meaning ‘no needle’, Nonacus accurately symbolises the company’s mission- to move away from intrusive, risky diagnostic procedures like tissue biopsies or amniocentesis towards less invasive testing. With the ultimate aim to not only improve patients experience and care but open
Read More

Target Enrichment

Target exactly what you want With Cell3™ Target Custom NGS Panels Exquisitely sensitive technology for rare variant detection. Cell3™ Target is a novel targeted enrichment system for NGS developed by Nonacus to provide a complete, straightforward and customisable solution for converting any type of DNA (cfDNA, gDNA, FFPE DNA) into libraries for next generation sequencing. Exceptional performance Cell3™ Target customised panels offer uniform coverage and more on target sequencing reads then other enrichment methods.  Molecular barcoding allows accurate and confident calling of ultra-low frequency mutations down to 0.1% VAF and NGS validation of every panel guarantees you probe uniformity. Learn
Read More

Alternative

Target exactly what you want With Cell3™ Target Custom NGS Panels Exquisitely sensitive technology for rare variant detection. If you are looking for an alternative to SeqCap, Cell3™ Target is a novel targeted enrichment system for NGS developed by Nonacus to provide a complete, straightforward and customisable solution for converting any type of DNA (cfDNA, gDNA, FFPE DNA) into libraries for next generation sequencing. Exceptional performance Cell3™ Target customised panels offer uniform coverage and more on target sequencing reads than other enrichment methods.  Molecular barcoding allows accurate and confident calling of ultra-low frequency mutations down to 0.1% VAF and NGS
Read More